Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium.
about
LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectivesModelling idiopathic Parkinson disease as a complex illness can inform incidence rate in healthy adults: the PREDIGT scoreNeuroimaging in pre-motor Parkinson's diseaseActivation of FADD-Dependent Neuronal Death Pathways as a Predictor of Pathogenicity for LRRK2 Mutations.DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers.A Personalized Approach to Parkinson's Disease Patients Based on Founder Mutation AnalysisIntegrated analysis of differential expression and alternative splicing of non-small cell lung cancer based on RNA sequencing.Estimation of genetic risk function with covariates in the presence of missing genotypes.Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers.The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.Precision medicine for disease modification in Parkinson disease.Clinical Features of LRRK2 Carriers with Parkinson's Disease.Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers.Arm swing as a potential new prodromal marker of Parkinson's disease.Cautionary optimism: caffeine and Parkinson's disease risk.Prospective clinical and DaT-SPECT imaging in premotor LRRK2 G2019S-associated Parkinson disease.Sex differences in LRRK2 G2019S and idiopathic Parkinson's Disease.Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers.Progression in the LRRK2-Asssociated Parkinson Disease Population.Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers.Age-Dependent Dopaminergic Neurodegeneration and Impairment of the Autophagy-Lysosomal Pathway in LRRK-Deficient Mice.Reply: Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorder.Motor and Nonmotor Features of Carriers of the p.A53T Alpha-Synuclein Mutation: A Longitudinal Study.Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease.Inflammatory profile discriminates clinical subtypes in LRRK2-associated Parkinson's disease.Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease.Application of the Movement Disorder Society prodromal criteria in healthy G2019S-LRRK2 carriers.Investigation of serotonergic Parkinson's disease-related covariance pattern using [11C]-DASB/PET.Clinical Heterogeneity Among Variants in Parkinson's Disease: A Meta-AnalysisCognition among individuals along a spectrum of increased risk for Parkinson's diseaseModeling Parkinson's Disease Using Patient-specific Induced Pluripotent Stem Cells
P2860
Q28078899-E4619DD4-584D-458A-BE64-80C83848EEE4Q29048624-9AE8D2CE-D052-49BB-9007-F0C9CF78A5A7Q33676222-BE42729C-E54F-4500-B849-052A6F0EA2E0Q36188579-43CAA36A-AD37-43DB-867A-E385EADF2CE7Q36345908-E19983A2-AC83-4203-8E50-84677340746AQ36885946-F7DB3BB9-CB9B-4E53-9EEC-D9883D439AA3Q38430213-7A6F4C1A-FF7C-4E5B-8E70-5AD88D7EC38CQ38665765-2F7C3D0A-0831-4700-A50E-097F5FE8432BQ38738200-293295D9-0D71-4955-9910-927CDD15229AQ38843010-EA1D47C2-5478-4225-88C5-4C3125562C34Q38859352-6FFCC23D-23E4-474D-88E2-FCE27BCA4CDAQ39096323-DE215BD7-9970-4A12-AB69-9515B44AFB25Q39206423-6C09E153-4DEE-4A10-A9AF-959E91155ABEQ39967268-2E5125F8-85AD-4BA4-8578-2BE224000B9FQ41355527-A271BE31-B710-458D-B181-C6956ABC2C83Q42740862-6B4CFF40-2904-4D03-BD4C-BC47D3D7DFC0Q44060284-39E9AF74-29AB-4C24-A608-349E4DFC6D1FQ45820322-4E3EE3CC-585D-42FF-A12B-6ADBD444E805Q46001147-1667E04F-E3C8-438F-86E4-DAAF6F5A1125Q47139369-E676C8DC-5DF5-4292-BED5-08A8F07A2E6CQ47198236-EA3F5643-C34B-4BFD-BD8F-15C04E6D14EBQ47281413-C8DC0CB2-D634-40F7-ABBD-09D3777659CFQ47620111-C15AEE22-77AD-447A-A743-AC4247C6B54CQ47745302-3257444B-D699-446E-A210-A4075E731960Q47872914-B283874D-2AC0-48F1-82DF-6CB348B3F41BQ48003270-4EA025B5-8250-4061-B4FC-178075655B17Q48350333-FF1B16D0-7FCF-4DEC-B3FC-456CF05B60C7Q50424585-F28703F4-C03E-4D74-8A71-0CA875743A52Q51758052-ADE26D0D-C9DF-4F59-8E8E-74508F335631Q55287139-B507D306-22FF-48D9-941B-7F16DD8F4F40Q57072461-90C4DB5A-757A-4477-9D5F-1C7103DE9B88Q57168544-9DA48121-55B1-4CBD-8E11-4161F17A3A6FQ58726898-BDFD2671-B819-4606-A473-CF1913462886
P2860
Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Age-specific penetrance of LRR ...... enazi Jewish LRRK2 Consortium.
@ast
Age-specific penetrance of LRR ...... enazi Jewish LRRK2 Consortium.
@en
type
label
Age-specific penetrance of LRR ...... enazi Jewish LRRK2 Consortium.
@ast
Age-specific penetrance of LRR ...... enazi Jewish LRRK2 Consortium.
@en
prefLabel
Age-specific penetrance of LRR ...... enazi Jewish LRRK2 Consortium.
@ast
Age-specific penetrance of LRR ...... enazi Jewish LRRK2 Consortium.
@en
P2093
P2860
P50
P1433
P1476
Age-specific penetrance of LRR ...... enazi Jewish LRRK2 Consortium.
@en
P2093
Anat Mirelman
Deborah Raymond
Helen Mejia-Santana
Karen Marder
LRRK2 Ashkenazi Jewish Consortium
Laurie Ozelius
Lorraine Clark
Ming-Xin Tang
Roy N Alcalay
P2860
P356
10.1212/WNL.0000000000001708
P407
P577
2015-06-10T00:00:00Z